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Risk
• Mission risk and Impacts:
 Potential risk condition exists during the pre-, in- and postflight 
phases
 Risk to crewmember for both acute and chronic health effects
 Potential for significant impact to mission operational objectives
• Early termination of mission
• Significant impact to affected crewmember’s performance
• Significant impact to other crewmembers for medical care 
and treatment of affected crewmember
EVIDENCE
 As of 2008, 15 symptomatic urinary 
calculi have been experienced by 13 
U.S. astronauts (Pietryzk, et al, 2006; 
Jones et al, 2008)
Multiple stone events among 
cosmonauts reported by Russian 
medical investigators 
 One in-flight episode nearly causing 
a mission termination but was resolved 
by spontaneous stone passage
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NEPHROLITHIASIS – A MULTIFACTORIAL DISEASE
SYMPTOMS/SIGNS
• Severe / agonizing pain in the flank (back just below the 
ribs spreading around to the front of the abdomen) often 
extending into the groin area.
• Usually nausea and often vomiting
• Fever chills and sepsis, if infection is present
• Gross or microscopic blood in the urine
• Progression if not treated, hydronephrosis, renal 
shutdown
Urolithiasis and Stone Passage
Stone Size Chance of 
Spontaneous 
Passage
Time to Pass 
Stone
Require 
surgical 
intervention
<2 mm >85% 4.5-8 days 5%
<5 mm 78-80 7 – 14.5 days 17%
5-7 mm 20-50%
(35% avg)
5.5-22 days 50%
>7 mm < 10% 
(8% avg)
53 days - never >80%
Stones 3 mm in size can cause transient or complete obstruction 
Recurrence approx 5-10%/year up to 75% at 20 years
STUDY OBJECTIVES
 Quantitate the pre-, in- and postflight risk of renal stone formation 
associated with space flight.
 Determine the efficacy of potassium citrate as a countermeasure 
in reducing the in-flight and postflight for renal stone formation.
 Evaluate dietary impact on the urinary biochemistry.
SUBJECTS
Placebo Group: n = 18
NASA-Mir missions   12 male subjects, mission duration  129 - 208 days
ISS missions               6 male subjects, mission duration 93 - 175 days 
KCIT Group: n = 12 
ISS missions 11 male/1 female subjects, mission duration 93 - 175 days 
 24-hour urines collected pre-, in-, and post-flight
 Food, fluid, exercise, and medications monitored before and
during the urine collection period
 Two potassium citrate (KCIT) pills, 10 mEq/pill, ingested daily
(with the last meal of the day) from L-3 days to R+14 days
• Double-blind study design except for last 3 ISS subjects
 Biochemical analysis of urine samples for urinary 
factors associated with stone formation
 Dietary analysis completed to assess 
environmental influences on the urinary 
biochemistry
METHODS
INVESTIGATION
RESULTS
The majority of oral citrate is metabolized in the liver to bicarbonate, 
each citrate ion producing three bicarbonate ions.
Potassium Citrate
HCO3
pH
U-Citrate U-Calcium
Renal Stone
Effects on renal physiology
65-90% of filtered citrate is reabsorbed
10-35% of citrate is excreted into the urine
Effects of dosage used (20 mEq/d)
expected urinary increase of 130-140 mg/d
expected rise in urinary pH of 0.2 – 0.3 unitsUrinary Supersaturation
KCIT dosage of 20 mEq/d selected based on;
 results from Shuttle and NASA-Mir missions
 minimize any potential for in-flight GI upset 
(wax matrix/ slow release prep)
 minimize the potential to exaggerate the risk
for CaP stones (higher pH 7.25-7.5)
 minimize impact to crew time
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FLUID 
BALANCE
Fluid intake during flight
Low urine volumes (< 2L/d)
Similar fluid intake and total urine
volumes between groups
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Effect of Potassium Citrate on Urinary pH
Urinary pH in
KCIT crewmembers, 
but not too high
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Risk of uric acid stone
formation in KCIT 
crewmembers
Uric Acid Stones
Image from Mission Pharmacal
Effect of Potassium Citrate on Uric Acid Supersaturation
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CALCIUM
BALANCE
Dietary Ca intake below 
recommended levels
Urinary Ca excretion in KCIT
crewmembers
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KCIT SUBJECTS
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Comparison of in-flight risk to 
individual’s preflight risk
KCIT subjects maintained calcium
oxalate risk at preflight levels
C
Risk of Calcium Oxalate
Stone Formation
CASE STUDY
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MIR IN-FLIGHT
HYPERCALCIURIA
CREWMEMBER PARTICPATED 
IN BOTH MIR AND ISS MISSIONS
MIR – No Treatment
ISS - KCIT
IN-FLIGHT CALCIUM EXCRETION 
DURING KCIT INGESTION
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Low urine volume during 
both missions
In-flight urinary pH during 
KCIT ingestion
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Decreased urinary supersaturation
during KCIT ingestion
Supersaturation values >2.0
indicate greater risk for
stone formation
 KCIT treated subjects exhibited decreased urinary calcium
excretion.
 KCIT subjects maintained the levels of calcium oxalate
supersaturation risk at their preflight levels.
 Increased urinary pH levels in KCIT treated subjects reduced the
risk of uric acid stones.
 Individual crewmember response may play a role in renal stone
susceptibility and efficacy of countermeasures.
SIGNIFICANT FINDINGS
Risk Mitigation Strategies 
and 
Recommended Actions
Recommendations
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 Encourage increased fluid intake to increase urine volume
Recommendations
 Use of Potassium Citrate
• urinary inhibitor of calcium-containing stones, binds with
calcium reducing the amount of calcium available to form CAOX
• inhibits crystal growth,  aggregation  and nucleation
• alkalinizes urine and decrease urinary calcium excretion
• supported by Space Medicine
• in Transition to Medical Practice process for operational use
 Assess dietary influences
• decrease protein, sodium and oxalate intake
• maintain calcium intake to recommended levels
 Perform urinary risk assessments
• identify crewmembers who are at any elevated risk
• provides an education program to help humans remain
healthy during space exploration
FUTURE POTENTIAL
(URINARY CALCIUM * URINARY OXALATE)/ 
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Potential In-Flight Prediction of Stone Risk
Capability to measure urine volume provided with the installation of the
UMS on Flight 20A and the addition of the in-line calcium sensor for 
real-time data collection
Development of an oxalate sensor would be required to optimize real-time risk
Urine Monitoring System (UMS)
“ I'd rather give birth to an elephant than go through this”.
“ Like being hit with a two-by-four” .
“ Like being shot with an arrow”.  
“ Pain came on suddenly and did not pass until doctors hopped me up on pain 
meds. I've had  my gall bladder removed and nearly severed my thumb but I 
never in my life felt pain like this.  Would wish it upon no one!! 
“  I have had my leg crushed by a car backing over it and that has nothing 
compared to the pain  of a kidney stone”  !!!!
PATIENT COMMENTS: 
Characterizing the symptoms
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